Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03602911 · ClinicalTrials.gov registry record · Phase 2
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
A Phase 2 study, sponsored by West Virginia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03602911 is a Phase 2 study that has completed, run by West Virginia University. The registered enrollment target is 20 participants.
The verdict
NCT03602911, a Phase 2 study, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.
Interventions
- DRUG The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03602911
The ClinicalTrials.gov registry entry for NCT03602911 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT is the first listed.
NCT03602911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03602911 about?
NCT03602911 is a clinical study titled "A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients". This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.
What is the current status of trial NCT03602911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-02-01. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT03602911?
The interventions under investigation include: The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT (DRUG).
Who is sponsoring clinical trial NCT03602911?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.